Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -69.40% | -65.60% | 43.15% | -64.15% | 30.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -69.40% | -65.60% | 43.15% | -64.15% | 30.57% |
| Cost of Revenue | -61.47% | -73.26% | -48.13% | -52.28% | 22.83% |
| Gross Profit | 61.10% | 73.49% | 49.23% | 51.73% | -22.48% |
| SG&A Expenses | -31.87% | -43.92% | -17.08% | -21.43% | 12.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.21% | -66.17% | -39.99% | -43.39% | 19.74% |
| Operating Income | 52.66% | 66.18% | 40.73% | 42.72% | -19.41% |
| Income Before Tax | 84.55% | 61.93% | 27.52% | 24.11% | -208.34% |
| Income Tax Expenses | -83.33% | -71.43% | -64.71% | -56.25% | 0.00% |
| Earnings from Continuing Operations | 84.55% | 61.93% | 27.56% | 24.14% | -208.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.55% | 61.93% | 27.56% | 24.14% | -208.18% |
| EBIT | 52.66% | 66.18% | 40.73% | 42.72% | -19.41% |
| EBITDA | 53.00% | 66.53% | 41.34% | 42.74% | -19.48% |
| EPS Basic | 85.00% | 62.94% | 31.96% | 46.81% | -105.62% |
| Normalized Basic EPS | 54.08% | 66.78% | 42.11% | 59.36% | 19.30% |
| EPS Diluted | 85.00% | 62.94% | 31.96% | 46.81% | -105.62% |
| Normalized Diluted EPS | 54.08% | 66.78% | 42.11% | 59.36% | 19.30% |
| Average Basic Shares Outstanding | 3.01% | 2.73% | 6.46% | 42.62% | 49.88% |
| Average Diluted Shares Outstanding | 3.01% | 2.73% | 6.46% | 42.62% | 49.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |